Cascadian Therapeutics, Inc. (CASC) Downgraded by Zacks Investment Research to “Sell”
Cascadian Therapeutics, Inc. (NASDAQ:CASC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “
Other equities analysts have also issued reports about the company. Barclays PLC assumed coverage on Cascadian Therapeutics in a report on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price objective for the company. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, August 9th. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a report on Monday, September 11th. Finally, ValuEngine lowered Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.06. During the same period in the previous year, the company earned ($1.57) EPS. On average, equities research analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Cascadian Therapeutics, Inc. (CASC) Downgraded by Zacks Investment Research to “Sell”” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/cascadian-therapeutics-inc-casc-downgraded-by-zacks-investment-research-to-sell.html.
Several institutional investors have recently bought and sold shares of the company. Perkins Capital Management Inc. boosted its holdings in shares of Cascadian Therapeutics by 8.3% in the second quarter. Perkins Capital Management Inc. now owns 52,129 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 4,000 shares during the period. OxFORD Asset Management LLP boosted its holdings in shares of Cascadian Therapeutics by 11.8% in the second quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 19,131 shares during the period. GRT Capital Partners L.L.C. boosted its holdings in shares of Cascadian Therapeutics by 50.5% in the second quarter. GRT Capital Partners L.L.C. now owns 58,109 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 19,500 shares during the period. State of Wisconsin Investment Board bought a new position in shares of Cascadian Therapeutics in the second quarter worth $104,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Cascadian Therapeutics in the first quarter worth $122,000. 82.55% of the stock is owned by hedge funds and other institutional investors.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.